Open Monoclonal Technology (OMT) and Pfizer have entered an agreement under which Pfizer will use OMT’s OmniRat for antibody R&D. OmniRat is a platform technology that generates fully human antibodies and enables developers to skip humanization of animal-derived antibodies or lead optimization of display candidates.
 
Dr. Roland Buelow, founder and chief executive officer of OMT, said, “OMT is pleased that Pfizer’s testing of our antibody platform showed that OmniRat makes antibodies just like normal rats and covers different epitopes than mice. OMT and Pfizer have performed in-depth characterization of OmniRat and generated antibodies binding to several different targets with subnanomolar affinities.”
 
Dr. Jaume Pons, chief scientific officer of Pfizer’s Rinat Laboratories, added, “Pfizer continues to remain a leader in biologics and the application of new and emerging technologies to accelerate discovery to address patient needs. We are pleased to include OmniRat as part of our capabilities.”